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Abstract
Background Until recently there has been no proven
second-line therapy for patients with advanced gastro-
esophageal cancer (GEC). Since 2004, Denmark has had a
national health program where non-proven therapy can be
offered to patients with advanced cancer, after approval by
an expert panel appointed by the National Board of Health.
This program has accelerated the introduction and imple-
mentation of new therapies in Denmark. Inspired by
therapy in metastatic colorectal cancer, a combination of
cetuximab and irinotecan (Cetiri) was chosen for second-
line therapy in GEC patients. We report our experience
with Cetiri as second-line therapy in patients with GEC.
Methods All patients had histologically confirmed GEC
and all patients had progressive disease during or after first-
line platinum-containing chemotherapy. The patients
received cetuximab 500 mg/m2 on day 1 and irinotecan
180 mg/m2 on day 1 every 2nd week until progression or
unacceptable toxicity. Toxicity was prospectively evaluated
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 3.0.
Results From December 2007 to February 2009, 50
consecutive patients received Cetiri as second-line therapy.
Median performance status (PS) was 1. The median num-
ber of courses was seven. Seven patients (14%) had a
partial response. Median progression-free survival (PFS)
was 3.3 months and overall survival (OS) was 5.5 months;
two patients are still alive without progressive disease.
Major toxicities were: diarrhea (8%), fatigue (10%), neu-
tropenia (16%), and febrile neutropenia (2%).
Conclusion Cetiri every two weeks is a convenient and
well-tolerated second-line regimen in GEC patients. A
promising effect was seen in patients with PS 0-1 and in
patients who developed a rash.
Keywords Stomach neoplasm  Cetuximab  Irinotecan 
KRAS protein  Second-line therapy
Introduction
Despite a declining incidence of gastro-esophageal cancer
(GEC) in developed countries it is still the second most
common cause of cancer-related deaths worldwide [1, 2].
For patients with non-resectable disease or recurrent disease,
palliative chemotherapy prolongs survival and improves
quality of life [3, 4]. Adenocarcinoma of the esophagus,
esophagogastric junction, and the stomach is often regarded
as a single entity in regard to the efficacy and toxicity of
chemotherapy [5]. At present, there are several standards for
chemotherapy regimens for first-line therapy, but most often
platinum-based therapies are used, with response rates
(RRs) between 25 and 45%, and a prolongation of median
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overall survival (OS) to 7–10 months [6, 7]. Patients who
progress on first-line therapy have a dismal prognosis, with
an expected median survival of a few months. However,
many patients still have an excellent performance status
(PS), leading to interest in second-line therapy. Until
recently, there was no established second-line therapy in
GEC patients, but a new small randomized study demon-
strated a prolonged OS in favor of irinotecan compared to
best supportive care [8]. Irinotecan is a topoisomerase-1
inhibitor with proven activity in GEC patients, both as a
single agent and in combination with other modalities,
including 5-fluorouracil (FU) and cisplatin [9–11]. Epider-
mal growth factor receptor (EGFR) is over-expressed in
40–60% of GEC patients. Cetuximab is a monoclonal anti-
body against the EGFR and has shown activity in metastatic
colorectal cancer (mCRC) where response to therapy is
strongly correlated with the mutational status of KRAS. The
combination of cetuximab and irinotecan is active in irino-
tecan-refractory mCRC patients, with a favorable toxicity
profile [12]. Usually cetuximab is administered on a weekly
schedule, but pharmacokinetic studies in patients with
mCRC have demonstrated no major differences between
cetuximab 250 mg/m2 weekly versus cetuximab 500 mg/m2
every second week [13–15]. Administration of a simplified
regimen that does not compromise efficacy is desirable for
both patients and hospital personnel.
Since 2004, Denmark has had a national health program
where non-proven therapy can be offered to patients with
advanced cancer, after approval by a Second Opinion Panel
appointed by the National Board of Health. This program
has had a major impact on the management of cancer
patients in Denmark and has accelerated the introduction
and implementation of new drugs [16]. Inspired by the high
incidence of EGFR over-expression in GEC patients and
the promising results seen in patients with mCRC, cetux-
imab and irinotecan (Cetiri) was administered every second
week [17] as experimental second-line therapy in GEC
patients whose disease had progressed during or after
platinum-based chemotherapy.
Patients, materials, and methods
In this compassionate-use series, 50 consecutive patients
were registered and treated in a single experimental cancer
unit. Treatment was, in all patients, recommended by the
Danish Second Opinion Panel. Before the start of treat-
ment, patients were evaluated and informed about the
experimental therapy with biweekly Cetiri. All patients
selected for treatment had histologically verified, evaluable
or non-evaluable, non-resectable adenocarcinoma of the
esophagus, esophageal junction, or stomach. All patients
had received prior platinum-based chemotherapy and had
demonstrated progressive disease during or after previous
treatment. Standard adequate laboratory tests, including
hematology and renal and hepatic function tests, were
required prior to treatment. Response was evaluated by the
investigators according to the Response Evaluation Criteria
in Solid Tumors (RECIST) 1.0. Patients with non-mea-
surable disease at the start of treatment and without signs of
progression after 4 cycles of Cetiri (2 months) were con-
sidered to have stable disease (SD).
Treatment
It was planned that patients were to receive a combination
of irinotecan 180 mg/m2 and cetuximab as a 500 mg/m2
infusion on day 1 (Cetiri) every second week [17]. The first
course of cetuximab was infused in 120 min (min) followed
1 h later by irinotecan. Subsequent courses of cetuximab
were infused in only 60 min, immediately followed by iri-
notecan given in 30 min, resulting in an overall treatment
time of 90 min. Therapy was repeated every second week
until unacceptable toxicity or disease progression. Patients
received premedication with oral prednisolone 100 mg and
an antihistamine, e.g., 2 mg clemastine i.v., to minimize the
risk of infusion-related reactions associated with cetuximab,
as well as antiemetics and oral ondansetron 8 mg 9 2
before the irinotecan infusion.. In order to prevent irino-
tecan-associated acute cholinergic syndrome, 0.25 mg
atropine was given s.c. or as a slow i.v. infusion. Two
patients were offered irinotecan (250 mg/m2) and pani-
tumumab (9 mg/kg) every three weeks due to their having
an exceptionally long transportation time to the hospital.
DNA extraction and KRAS mutation analysis
KRAS mutation analysis was performed on tissue samples from
the first 28 patients treated with Cetiri. The tumor samples were
obtained from the primary gastric tumors (n = 23) or meta-
static tissue (n = 5). DNA was extracted from formalin-fixed
paraffin-embedded (FFPE) tissue sections, using a MagNA
Pure LC DNA Isolation Kit (Tissue) (Roche). Samples were
included for the analysis after histological verification of the
presence of more than 70% tumor cells in each tumor sample.
KRAS mutation analysis was performed as a real-time poly-
merase chain reaction (PCR), using a TheraScreen KRAS
mutation kit (DxS, Manchester, England) according to the
manufacturer’s protocol. The seven most common KRAS point
mutations in codons 12 and 13 were detected in the analysis.
Each sample was analyzed in duplicate.
Evaluation of toxicity and dose adjustment
Adverse events were prospectively evaluated and recorded
before each course according to the National Cancer
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Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. In patients with CTCAE grade 3 or 4
adverse events, the dose of irinotecan was reduced by 25%
in the subsequent treatment cycles. If patients developed
grade 3 skin toxicity, the dose of cetuximab was postponed
until recovery to grade B2; in those with recurrent episodes
of grade 3 skin toxicity, the dose of cetuximab was reduced
by 20% in the subsequent treatment cycles.
Statistical considerations
Progression-free survival (PFS) was calculated as the period
from the first infusion of Cetiri to the first observation of
radiological or clinical disease progression or death of any
cause. OS was calculated as the period from the first infusion
of Cetiri until death of any cause. Data were updated in
December 2010. Survival analyses were performed using
the Kaplan–Meier method. In order to establish prognostic
factors for OS, a multivariate model was fitted, using Cox
regression, to known and collected clinically relevant
prognostic factors. Because of the limited numbers of
patients only six parameters were included in the multivar-
iate Cox regression model. Performance status (PS) was
divided into three groups; PS = 0, versus PS = 1 versus
PS = 2. Time to progression (TTP) under first-line che-
motherapy was included as a continuous variable and was
defined as the period from the start of first-line chemother-
apy to the first date of Cetiri. The number of metastatic sites
was divided into two groups; 1–2 versus C3. Skin toxicity
was included in the model as any rash versus no rash, and
blood samples were dichotomized at the upper normal limit.
Results
Patient characteristics
From December 2007 to February 2009, 50 consecutive
patients were treated at our experimental unit. Patient
characteristics are listed in Table 1. Median age was
61 years (range 29–76). The majority of patients (40) were
men (80%). The location of the primary tumor was the
esophagus in two patients, gastro-esophageal junction in
32, and stomach in 16. Forty-five patients had metastatic
disease. At baseline 17 patients had PS 0 (34%), 27 patients
had PS 1 (54%), and six patients had PS 2 (12%). All
patients had received prior platinum-based combination
chemotherapy.
Toxicity
All patients were evaluable for toxicity. In general, the
treatment was well tolerated; the worst CTCAE toxicities
are listed in Table 2) Non-hematological toxicities were
mainly grade 1–2; fatigue (72%), diarrhea (48%), nausea
(70%), vomiting (30%), and skin toxicity (65%). Only four
patients (8%) had diarrhea grade 3. Hematological toxici-
ties of grade 3–4 were neutropenia (16%) and febrile
neutropenia (2%). Two patients died before receiving the
second course of therapy, one patient due to intestinal
volvulus and one patient due to pulmonary embolism.
KRAS mutation analysis
Mutation analysis of KRAS codons 12 and 13 was retro-
spectively planned in all patients. However, in eight of the
first 28 patients it was not possible to conduct the KRAS
mutation analysis because of very sparse tumor tissue.
Among the 20 patients analyzed, only two tumors (10%)
had a KRAS mutation, one in p.Gly12Asp and one in
p.Gly12Cys. Eighteen tumors were KRAS wild-type. The
two patients with the KRAS mutation received 1 and 28
courses of Cetiri, respectively. The patient receiving only
one cycle was hospitalized shortly after the first treatment
with intestinal volvulus and died following this. The other
patient, who received 28 courses, obtained a partial
response (PR) during treatment and had an R0 resection.
Because of the low incidence of KRAS mutations among
the analyzed patients, corresponding to results from the
literature [18], we decided not to perform KRAS analysis in
the remaining patients.
Table 1 Baseline characteristics
Number of patients 50
Age, years (median) range 61 (range 29–76)
Male/Female 40/10
PS
Median 1
0 17 (34%)
1 27 (54%)
2 6 (12%)
Primary tumor site, n (%)
Esophagus 2 (4)
Gastro-esophageal junction 32 (64)
Stomach 16 (32)
Stage, n (%)
Locally advanced 5 (10)
Metastatic 45 (90)
Number of metastatic sites, n (%)
1–2 25 (50)
C3 25 (50)
Median TTP under first-line CT (range) 4.5 months (1.5–13)
months
PS performance status, TTP time to progression, CT chemotherapy
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Efficacy
In total, 478 treatment cycles were administered to 50
patients, with a median of seven cycles per patient (range
1–46) (Table 3). Forty-five patients were evaluable for
response because treatment was stopped in five patients
before the planned response evaluation after four courses.
Reasons for early cessation were toxicity in two patients,
death in two other patients (intestinal volvulus and pul-
monary embolism), and one due to patient’s request. The
overall RR was 14%. Ten patients had progressive disease
either before or at the time of their first evaluation. The
median PFS was 3.3 months and OS was 5.5 months
(Fig. 1). After a median follow-up of 29 months, one
patient is continuing treatment without signs of progressive
disease (PD) and two patients are still alive.
In the multivariate analysis PS = 1 and PS = 2 were
significantly associated with a short OS. Furthermore, the
development of rash was significantly associated with a
prolonged OS (Table 4).
Discussion
After progression to first-line chemotherapy, patients with
GEC have a dismal prognosis, with an expected OS of a few
months. A subgroup of patients is, however, in a good PS at
the time of progression and for these patients there is a need
for effective second-line chemotherapy. At present, it is
often daily clinical practice to offer second-line therapy to
patients in a good PS, and 30–40% of all GEC patients
receive second-line therapy after first-line progression
Table 2 Worst adverse events per patient
Grade 1 ? 2 Grade 3–4 Grade 5
n (%) n (%) n (%)
Hematological toxicity
Leucopenia 4 (8) 4 (8) 0
Neutropenia 4 (8) 8 (16) 0
Thrombocytopenia 0 0 0
Febrile neutropenia – 1 (2) 0
Non-hematological toxicity
Diarrhea 24 (48) 4 (8) 0
Nausea 35 (70) 0 0
Vomiting 15 (30) 1 (2) 0
Fatigue 36 (72) 5 (10) 0
Skin toxicity 31 (65) 1 (2) 0
Intestinal volvulus 0 0 1(2)
Pulmonary embolism 0 0 1(2)
Table 3 Efficacy of Cetiri as second-line therapy in GEC patients
n (%)
Evaluable disease 48 (96)
Non-evaluable disease 2 (4)
Number of courses
Total 478
Median 7 (1–46)
Response rate
PR 7 (14)
SD 28 (56)
Median PFS 3.3 months (CI 1.9–4.4)
Median OS 5.5 months (CI 3.6–7.3)
Cetiri cetuximab and irinotecan, GEC gastro-esophageal cancer, PR
partial response, SD stable disease, PFS progression-free survival, OS
overall survival, CI confidence interval
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Fig. 1 Overall survival (OS) and progression-free survival (PFS).
Kaplan–Meier curves of overall survival (median 5.5 months) and
time to progression (median 3.3 months). CI Confidence interval
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[19–21]. Several phase II trials have investigated different
drugs and combinations in the second-line setting, and
promising agents such as irinotecan, taxanes, and platins
have been tested [10, 11, 22, 23]. So far, no standard regi-
men has been established as second-line treatment. The
need to find prognostic and predictive factors indicating
who will benefit from both first- and second-line therapy is
imperative. Recently analyses have been performed in order
to clarify this question. Chau et al. [19] pooled data on 1080
patients from three randomized first-line trials and demon-
strated that PS C 2, the presence of liver and/or peritoneal
metastases, and elevated alkaline phosphatase were prog-
nostic factors correlated with poor outcome in the first-line
setting. Subsequent analyses evaluating patients receiving
different regimens of chemotherapy in the second-line set-
ting have described PS C 2, number of metastatic sites,
short TTP under first-line chemotherapy, and different
laboratory test results, such as low hemoglobinand elevated
WBC or alkaline phosphatase as prognostic factors asso-
ciated with overall survival [24–27].
Today the use of molecular targeting agents is a new
challenge in modern cancer therapy and these agents may
have a significant impact on the treatment of GEC patients
in the future [28]. EGFR is over-expressed in many GEC
patients and has, in some studies, been associated with a
poor prognosis, underlining the significant role that the
EGFR might have in human GEC biology. Preclinical trials
in EGFR over-expressing gastric cancer cell lines and
tumor xenografts have suggested an anti-tumor effect of
cetuximab as a result of different intracellular and immu-
nological mechanisms [29, 30]. Moreover, one recently
described mechanism of resistance to cetuximab, mutation
of the KRAS gene, seems to have a very low prevalence of
8% in GEC cancer [17, 31]. These findings are concurrent
with the results seen in our study, where a KRAS mutation
was found in only 10% of the 20 analyzed tumors.
As first-line therapy, cetuximab in combination with
chemotherapy has been evaluated in phase II trials and has
obtained promising results. In the Italian FOLCETUX
study, Pinto et al. evaluated cetuximab in combination with
irinotecan and 5-fluorouracil (5-FU) and recorded an RR of
44% (28–61%) and promising TTP and OS of 8 and
16 months, respectively, indicating potentially better effi-
cacy than that achieved with irinotecan and 5-FU alone
[32–34]. Recently other phase II studies have evaluated
cetuximab in combination with either docetaxel and
cisplatin, or oxaliplatin and 5-FU in the first-line setting
and obtained similar results [35–37].
Unfortunately, limited data exist on the efficacy and
predictors for the success of cetuximab as salvage therapy
in pretreated patients. Stein et al. evaluated weekly irino-
tecan and cetuximab in 13 heavily pretreated GEC patients.
In that study five patients obtained a PR, the overall disease
control rate was 62%, and TTP and OS were 2.6 and
3.4 months, respectively [38]. Park et al. performed a ret-
rospective analysis of 32 heavily pretreated patients mainly
in PS 2–3. The disease control rate was 28.6%, PFS was
1.7 months, and OS was 3.2 months. In a multivariate
analysis PS, skin rash, and metastatic sites were signifi-
cantly associated with both PFS and OS [39]. Gold et al.
[40] evaluated second-line cetuximab as monotherapy in
patients with metastatic esophageal adenocarcinoma, but
the trial failed to meet its primary endpoint of a median OS
of 6.0 months. In a multivariate analysis, our study dem-
onstrated that PS was a very strong prognostic factor. Both
PS 1 and PS 2 were significantly associated with short
overall survival (PS1: hazard ratio [HR] = 2.4; PS2:
HR = 10.3) (Table 4). As a consequence we only recom-
mend Cetiri for patients with PS B 1. Furthermore, we
found that the development of rash was significantly
associated with OS. It is remarkable that developing a rash
had a strong association with prolonged OS (HR = 0.4).
Rash, on the basis of treatment with drugs directed against
the EGFR, has also been described as a good prognostic
factor in studies including patients with mCRC and pan-
creatic cancer. One could put forward a hypothesis whether
GEC patients in the future could be selected for EGFR
treatment based on the occurrence of rash after one or two
courses of Cetiri. Surprisingly, our series failed to dem-
onstrate that the number of metastatic sites, TTP under
first-line chemotherapy, and different laboratory test results
were prognostic factors. Cetiri was well tolerated and
easily administered in the out-patient setting.
With a disease control rate of 70% and an RR of 14%
the present consecutive series indicates that patients in a
good PS and patients who develop a rash during treatment
benefit from irinotecan and cetuximab every second week.
However, these findings need validation in prospective
trials.
Conflict of interest None of the authors who contributed to this
work has any conflicts of interest.
Table 4 Results of exploratory Cox-multivariate analysis of known
and collected parameters for overall survival
Parameter Hazard ratio
(HR)
95% Confidence
interval (CI)
Performance status 1 2.4* 1.12–5.32
Performance status 2 10.3* 2.45–43.64
WBC [ 10 9 109/L 1.7 0.9–3.45
Platelets [ 400 9 109/L 1.2 0.44–3.1
Rash 0.4* 0.17–0.81
Number of metastatic sites 1.6 0.77–3.17
TTP under first-line CT 1.0 0.99–1.0
* p \ 0.05
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